SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-060535
Filing Date
2024-05-15
Accepted
2024-05-15 16:31:36
Documents
62
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q cgem-20240331.htm   iXBRL 10-Q 1116533
2 EX-3.1 cgem-ex3_1.htm EX-3.1 69383
3 EX-10.1 cgem-ex10_1.htm EX-10.1 66938
4 EX-31.1 cgem-ex31_1.htm EX-31.1 13490
5 EX-31.2 cgem-ex31_2.htm EX-31.2 13281
6 EX-32.1 cgem-ex32_1.htm EX-32.1 12351
  Complete submission text file 0000950170-24-060535.txt   5780988

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT cgem-20240331.xsd EX-101.SCH 1125177
66 EXTRACTED XBRL INSTANCE DOCUMENT cgem-20240331_htm.xml XML 753013
Mailing Address ONE MAIN STREET SUITE 1350 CAMBRIDGE MA 02142
Business Address ONE MAIN STREET SUITE 1350 CAMBRIDGE MA 02142 617-410-4650
Cullinan Therapeutics, Inc. (Filer) CIK: 0001789972 (see all company filings)

IRS No.: 813867811 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39856 | Film No.: 24951748
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)